Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 3045-3054

  Ferguson, Debra ^a   Rodriguez, Luis E ^a   Palma, Joann P ^a   Refici, Marion ^a   Jarvis, Kenneth ^a   O'Connor, Jacqueline ^a   Sullivan, Gerard M ^a   Frost, David ^a   Marsh, Kennan ^a   Bauch, Joy ^a   Zhang, Haiying ^a   Lin, Nan Horng ^a   Rosenberg, Saul ^a   Sham, Hing L ^a   Joseph, Ingrid B J K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 367074; ABT 100; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE H RAS; PANCREAS CANCER; PRIORITY JOURNAL; RACEMIC MIXTURE; TUMOR VASCULARIZATION; WILD TYPE;

ADMINISTRATION, ORAL; ALKYL AND ARYL TRANSFERASES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMIDAZOLES; INTERLEUKIN-8; MALE; MICE; MICE, NUDE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20244382552     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2041     Document Type: Article

References (56)

1. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-69.
2. Clarke S, Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem 1992;61:355-86.
3. Anant JS, Ong OC, Xie HY, Clarke S, O'Brien PJ, Fung BK. In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits. J Biol Chem 1992;267:687-90.
4. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000;275:30451-7.
5. Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000;275:21444-52.
6. Inglese J, Glickman JF, Lorenz W, Caron MG, Lefkowitz RJ. Isoprenylation of a protein kinase. Requirement of farnesylation/α-carboxyl methylation for full enzymatic activity of rhodopsin kinase. J Biol Chem 1992;267:1422-5.
7. Lai RK, Perez-Sala D, Canada FJ, Rando RR. The γ subunit of transducin is farnesylated. Proc Natl Acad Sci U S A 1990;87:7673-7.
8. James GL, Goldstein JL, Pathak RK, Anderson RG, Brown MS. PxF, a prenylated protein of peroxisomes. J Biol Chem 1994;269:14182-90.
9. Davis AR, Alevy YG, Chellaiah A, Quinn MT, Mohanakumar T. Characterization of HDJ-2, a human 40 kD heat shock protein. Int J Biochem Cell Biol 1998;30:1203-21.
10. Sinensky M, Fantle K, Trujillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994;107:61-7.
11. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989;264:20422-9.
12. Reuther GW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol 2000;12:157-65.
13. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
14. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
15. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyl-transferase inhibitor. Science 1993;260:1934-7.
16. Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995;270:26802-6.
17. Sepp-Lorenzino L, Ma Z, Rands E, et al. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995;55:5302-9.
18. Kelland LR, Smith V, Valenti M, et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 2001;7:3544-50.
19. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 1997;272:15591-4.
20. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999;19:1831-40.
21. Liu A, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and anti-neoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000;20:6105-13.
22. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000;275:17974-8.
23. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000;20:139-48.
24. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995;55:4575-80.
25. Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 2002;62:450-8.
26. Wright J, Blatner GL, Cheson BD. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777. Oncology (Huntingt) 1999;13:1527, 1530, 1533.
27. Adjei AA, Erlichman C, Davis JN, et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000;60:1871-7.
28. Karp JE. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Semin Hematol 2001;38:16-23.
29. Eskens FA, Stoter G, Verweij J. Farnesyl transferase inhibitors: current developments and future perspectives. CancerTreat Rev 2000;26:319-32.
30. Schellens JH, de Klerk GJ, Swart M, et al. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 2000;19:184.
31. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opin Investig Drugs 2000;9:2767-82.
32. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-41.
33. Johnston SR. Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2001;2:18-26.
34. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20:2726-35.
35. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101:1692-7.
36. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005;4:77-84.
37. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-9.
38. Caponigro F. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs 2002;13:891-7.
39. Ryan DP, Eder JP Jr, Puchlaski T, et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 2004;10: 2222-30.
40. Gu WZ, Joseph IBJK, Wang YC, et al. The effect of A-409100, a potent and highly selective farnesyltransferase inhibitor in vitro and in vivo. Washington (DC): AACR; 2003 Mar. p. 1417.
41. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997;272:14093-7.
42. Mullen OL, Dodd MC, Minton JP. Evaluation of dye exclusion and colony inhibition techniques for detection of polyoma-specific, cell-mediated immunity. J Natl Cancer Inst 1975;54:229-31.
43. Sun J, Ohkanda J, Coppola D, et al. Geranylgeranyl-transferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 2003;63:8922-9.
44. Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp Cell Res 2002;273:138-46.
45. Liu M, Bryant MS, Chen J, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58:4947-56.
46. 1 block in p53 wild type tumor cells. J Biol Chem 1998;273:20243-51.
47. Sirotnak FM, Sepp-Lorenzino L, Kohl NE, Rosen N, Scher HI. A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer Chemother Pharmacol 2000;46:79-83.
48. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61:131-7.
49. Kumar P, Miller AI, Polverini PJ. p38 MAPK mediates γ-irradiation- induced endothelial cell apoptosis and VEGF protects endothelial cells through PI3K-Akt-Bcl-2 pathway. J Biol Chem 2004;279:43352-60.
50. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998;3:d887-912.
51. Pruitt K, Der CJ. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett 2001;171:1-10.
52. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002;8:483-9.
53. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
54. Charvat S, Duchesne M, Parvaz P, Chignol MC, Schmitt D, Serres M. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor. Anticancer Res 1999;19:557-61.
55. Feldkamp MM, Lau N, Guha A. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities. Ann N Y Acad Sci 1999;886:257-60.
56. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.